The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Celgene (I); Merck
Stock and Other Ownership Interests - Celgene (I); Merck
Travel, Accommodations, Expenses - Celgene (I); Merck
 
Honoraria - Abbvie; Advaxis; Agenus; Amgen; AstraZeneca; Biodesix; Clovis Oncology; Conjupro Biotherapeutics; Genmab; Gradalis; ImmunoGen; Immunomedics; Incyte; Janssen Research & Development; Mateon Therapeutics; Merck; Myriad Genetics; Perthera; Pfizer; Precision Oncology; Puma Biotechnology; Roche/Genentech; Samumed; Takeda; Tesaro; VBL Therapeutics
Consulting or Advisory Role - Abbvie; Advaxis; Agenus; Amgen; AstraZeneca; Biodesix; Clovis Oncology; Conjupro Biotherapeutics; Genmab; Gradalis; ImmunoGen; Immunomedics; Incyte; Janssen Research & Development; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Perthera; Pfizer; Precision Oncology; Puma Biotechnology; Roche/Genentech; Samumed; Takeda; Tesaro; VBL Therapeutics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen Research & Development; Roche/Genentech; Tesaro
KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
 
Ronnie Shapira-Frommer
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Clovis Oncology; Vascular Biogenics
 
Jerome Alexandre
Honoraria - AstraZeneca; Ipsen; Novartis; Roche/Genentech; Sanofi/Aventis
Consulting or Advisory Role - AstraZeneca; Ipsen; Novartis; Roche; Sanofi
Research Funding - Janssen (Inst)
Travel, Accommodations, Expenses - Janssen; Novartis
 
Bradley Monk
No Relationships to Disclose
 
Tanja N. Fehm
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Novartis; Pfizer; Roche
Research Funding - Novartis
 
Nicoletta Colombo
Honoraria - AstraZeneca; PharmaMar; Roche/Genentech; Tesaro
Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; MSD Oncology; Pfizer; PharmaMar; Roche/Genentech; Takeda; Tesaro
 
Maria V. Caceres
No Relationships to Disclose
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; MSD
Consulting or Advisory Role - MSD
Research Funding - Daiichi Sankyo; Pfizer; Yakult Honsha
 
Coraline Dubot
No Relationships to Disclose
 
Jerry Jing Li
No Relationships to Disclose
 
Karen Stein
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Stephen Michael Keefe
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Krishnansu Sujata Tewari
Honoraria - Clovis Oncology; Tesaro
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - AstraZeneca; Merck; Roche/Genentech
Research Funding - Abbvie (Inst); Genentech/Roche (Inst); Merck (Inst); Morphotek (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Roche/Genentech